Treatment of hepatitis B vaccine triggered a number of hidden opportunities for

        We are on the biopharmaceutical industry and the related listed companies investment views and opinions, in June 29, 2005 issued a "vaccine monopoly break blood supply nervous, half of the investment strategy report" of 2005 in the biopharmaceutical industry, has a detailed statement, now basically no change. In 22 the price catalogue of the national development and Reform Commission in September 28th has just been published, involving some biological products, has a negative impact on the double Heron pharmaceutical and other listed companies, but not too much. Therefore, it should be part of the requirements of institutional investors, we are in this report, is only a preliminary study of the treatment of hepatitis B vaccine, the relevant issues.

        For the treatment of - existing, developed the hepatitis B vaccine has three kinds: immune complexes (hepatitis B antigen antibody complexes) vaccine, synthetic peptide vaccine and protein vaccine. The relevant listed company Tiantan biological, Yueda investment and Chongqing beer. Three vaccines have entered clinical trials, the development of the route, mechanism and advantages and disadvantages of different.

Immune complexes - Tiantan biological and Yueda investment (hepatitis B antigen antibody complex vaccine), jointly developed by Fudan University and Beijing Research Institute, has completed phase II a (i.e. the completion of the immunization schedule and doses of exploration) experiment, are B II (i.e., the effectiveness of the pre experimental period) is expected to experiment; to complete the phase II next year. We initially estimated that the vaccine will complete all clinical trials and obtain new drug certificates, the fastest will be in 2007.

Synthetic peptide vaccine named - Chongqing beer for a "therapeutic peptide vaccine, clinical trials program will be drugs, rather than referring to the vaccine program. Company completed the first phase of 30 cases of the experiment with a year, half a year later than the scheduled time. I have not yet started the second phase of the experiment, is expected to be in the Southwest Hospital and Peking University Hospital in Chongqing in the beginning of the second phase. Phase II experiments will be done in 100 cases, and the efficacy and safety of the third phase will be observed in 300 cases. If no unexpected circumstances, we are optimistic about the estimated completion of all clinical trials, the new drug certificate, the fastest will be in 2008.

- overall, for three kinds of hepatitis B vaccine therapy, all over the world belong to new things, there is no reference for reference, confirmation is safe and effective, must be completed phase III clinical experiment. Blind optimism and pessimism and despair do not conform to the laws of science.

        The failure, clinical efficacy and safety of the market expansion of the crowd spread slowly and other unfavorable factors, will lead to the vaccine sales not up to expectations.